Supreme Court questions Centre on wide gap between MRP and retail price of medicines, reserves order

KanoonHQ Legal Gazette · AI-generated brief from the source linked below. How briefs are made

Published 27 October 2026

Case: Unnamed Petitioners v. Union of India
Court: Supreme Court of India
Bench: Justice Vikram Nath and Justice Sandeep Mehta
Source: Verdictum

Bottom Line Up Front (BLUF)

The Supreme Court, comprising Justices Vikram Nath and Sandeep Mehta, questioned the Centre regarding the significant disparity between the Maximum Retail Price (MRP) and the retail price of medicines, observing that the National Pharmaceutical Pricing Authority (NPPA) appears 'totally defunct'. The Court reserved its order in the matter, which concerns the pricing of medicines in India.

Ratio Decidendi · Legal Principle Established

The court's observations indicate a concern regarding potential market failures or regulatory inadequacies allowing for excessive trade margins in pharmaceutical pricing, questioning the effectiveness of existing government policy and regulatory bodies like the NPPA in controlling medicine prices.

Practice & Procedural Impact for Advocates

Advocates should prepare for potential future litigation or policy changes concerning pharmaceutical pricing and trade margins. Litigants in the pharmaceutical sector may face increased scrutiny over pricing practices and the role of regulatory bodies.

Key Legal Takeaways

1The Supreme Court expressed concern over the large difference between MRP and retail prices of medicines.
2The Court questioned the Centre's policy on not controlling the entire pharmaceutical ecosystem.
3The National Pharmaceutical Pricing Authority (NPPA) was observed to be 'totally defunct' by the bench.

The Legal Issue The Supreme Court was hearing two petitions that highlighted the issue of medicine pricing in India, specifically the substantial difference between the Maximum Retail Price (MRP) and the price at which medicines are sold to retailers. The Court questioned the Union Government's policy regarding the control of the pharmaceutical ecosystem and the apparent ineffectiveness of the National Pharmaceutical Pricing Authority (NPPA).

Court's Reasoning A bench of Justice Vikram Nath and Justice Sandeep Mehta questioned the Centre, asking, "Why is the entire system working to help these people (manufacturers)?" The Court observed that the NPPA seemed to be a "totally defunct" body, implying a failure in its regulatory function to control medicine prices effectively. The bench noted that the government was allowing this disparity to occur "under the government's own eyes." The Additional Solicitor General, Aishwarya Bhati, representing the Centre, contended that medicine prices in India were among the lowest globally, but the Court's concerns persisted regarding the trade margins.

What Follows The Supreme Court has reserved its order in the matter. This indicates that a decision or further directions from the Court are pending, which could potentially lead to policy interventions or regulatory reforms concerning pharmaceutical pricing and the functioning of the NPPA. The Centre may be required to review its policies on controlling trade margins and ensuring affordable access to medicines.